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Abstract. Routine serological diagnoses for leishmaniases, except in visceral cases, are performed using whole-
parasite antigens. We used enzyme-linked immunosorbent assay (ELISA) to evaluate the performance of Leishmania
infantum rHsp83 compared with L. major-like total promastigote antigen in the diagnosis of cutaneous (CL), mucosal
(ML), and visceral leishmaniases (VL). ELISA-rHsp83 was significantly more sensitive than ELISA–L. major-like when
considering either CL/ML (P = 0.041) or all leishmaniasis patients (P = 0.013). When samples from other infectious
disease patients were evaluated for cross-reactivity, ELISA-rHsp83 was more specific than ELISA–L. major-like,
specifically for Chagas disease samples (P < 0.001). We also evaluated the anti-rHsp83 antibody titers months after
treatment and observed no significant difference in ML (P = 0.607) or CL (P = 0.205). We recommend ELISA–L.
infantum-rHsp83 as a routine confirmatory serological assay for the diagnosis of Leishmania infection because of the
high sensitivity, the specificity, and the insignificant cross-reactivity with other infectious diseases.
INTRODUCTION
Leishmaniases are caused by protozoa of the genus
Leishmania and may present as a visceral or tegumentary
disease. Typically found in tropical and subtropical areas,
leishmaniases are endemic in 98 countries.1 Visceral leish-
maniasis (VL) is a systemic disease that affects the mononu-
clear phagocyte system,2 whereas tegumentary leishmaniasis
(TL) comprise localized cutaneous leishmaniasis (CL), leish-
maniasis recidivans, disseminated cutaneous leishmaniasis
(DL), diffuse CL (DCL), and mucosal leishmaniasis (ML);
the specific manifestation is dependent on the Leishmania
species and the host immune response.3
Diagnosis of leishmaniases is based on epidemiological
data, clinical features, and laboratory test results, which
include a parasitological examination and serological assays.4
Parasitological examinations are accurate but laborious to
perform, and they have low sensitivity.5–8 However, when
polymerase chain reactions (PCRs) are used for the search of
Leishmania DNA, the sensitivity of the detection is consid-
ered higher. The sensitivity is even higher if the target gene is
a kinetoplast DNA sequence that is present in multiple copies
in Leishmania. Nevertheless, PCRs are not routinely used
because of their technical complexity.4,5 Thus, assays com-
monly used in the serological diagnosis of VL are the indirect
immunofluorescence assay (IIFA), the enzyme-linked immu-
nosorbent assay (ELISA), and the direct agglutination test
(DAT) using total Leishmania promastigote antigen.3,9,10
Serology is not a routine procedure for diagnosis of TLs,
such as localized CL, because of the low sensitivity of the
tests.11,12 In ML, serology may have a complementary role in
diagnosis, because the sensitivity is higher.13,14 However, var-
iable results have been achieved with serological methods; the
sensitivity and specificity of such methods depend on the type,
source, purity, and antigen preparation used.12,13,15–17 In addi-
tion, Leishmania species-related variations in the results have
been reported.18
One of the drawbacks in most currently available serolog-
ical assays is that the antigen is either a total parasite lysate
or whole promastigote, whose production depends on the
intricate growth of the parasite. Development of recombi-
nant Leishmania antigen for serological diagnosis would be
valuable, because the production of such an antigen would be
parasite growth-independent and more standardized and uni-
form. For VL, identification of the rK39 antigen has been a
promising diagnostic contribution. It has been used in ELISA
and immunochromatographic strip tests, which have facili-
tated field applicability,10,19 and they are now commonly
used worldwide.20
Previously, L. major Hsp6021 and L. braziliensis Hsp7022
were cloned and tested in 15 CL samples from Colombia,
which were found to have a mean optical density significantly
higher than the optical density of sera from healthy negative
controls. These two antigens were also tested in 46 ML sam-
ples from Brazil and had 89% sensitivity. More recently,
Souza and others23 evaluated seven L. infantum-derived
recombinant proteins in 102 TL serum samples and found that
Hsp70 was a promising antigen, with 65.0% sensitivity and
92.0% specificity. Previously, we had tested L. (L.) infantum
Hsp83 using a limited number of CL and ML samples and
obtained 100% reactivity.24 Interestingly, we also found no
cross-reactivity with Chagas disease serum samples.24
Because the previous data showed good sensitivity and speci-
ficity in CL and ML, in this study, we investigated L. (L.)
infantum Hsp83 in CL, ML, and VL samples to test its sensi-
tivity as well as in samples from other infectious diseases (i.e.,
Chagas disease, blastomycosis, histoplasmosis, aspergillosis,
chromomycosis, toxoplasmosis, cytomegalovirosis, malaria,
and tuberculosis) to test for cross-reactivity.
In TL, anti-Leishmania antibodies level has been previ-
ously shown to drop after treatment, independent of cure or
failure.18 Therefore, we also performed serology on patient
samples obtained during a follow-up visit to test anti-rHsp83
antigen antibody titers.
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Similar to most of the currently available total parasite-
based tests, the rHsp83 antigen test is not species-specific,
and therefore, our test would be beneficial for leishmani-
asis diagnostics.
MATERIALS ANDMETHODS
Antigens. L. infantum Hsp83 was expressed in Escherichia
coli M15 as a recombinant protein and purified by Ni-
NTA affinity chromatography (QIAGEN GmbH, Hilden,
North Rhine-Westphalia, Germany).25 The total L. major-
like (MHOM/BR/71/49)26 promastigote antigen was prepared
according to the work by Hoshino-Shimizu and others,27 with
modifications.28 The extract of this strain was used, because
the reaction is genus-specific, and it can detect leishmaniasis
caused by different species of Leishmania.29,30
Patients and serum samples. Sera from patients with CL
(12) and ML (14) were obtained from patients treated at the
Department of Dermatology, Faculdade de Medicina,
Universidade de Sa˜o Paulo. The clinical diagnosis was con-
firmed by parasitological and immunological methods. The
lesions were examined for the presence of parasites directly
and/or in biopsy specimens.31 All patients except two had a
positive intradermal Montenegro test.32 The majority (86.6%)
of patients was treated with pentavalent antimony (Sanofi
Aventis Farmaceˆutica Ltda, Suzano, Sa˜o Paulo, Brazil),;
7.7% of patients were treated with Amphotericin B (Bristol-
Myers-Squibb, Sa˜o Paulo, Sa˜o Paulo, Brazil), and 7.7% of
patients received both treatments (Table 1). Sera from
patients with VL (30) were from active VL patients in Piauı´
state, Northeastern Brazil, and patients had been diagnosed
based on clinical presentation and positive serology and/or the
presence of parasites in bone marrow. Sera from patients with
other infectious diseases were collected from 79 patients:
Chagas disease (N = 23), blastomycosis (N = 7), histoplasmosis
(N = 6), aspergillosis (N = 5), chromomycosis (N = 7), toxoplas-
mosis (N = 14), cytomegalovirosis (N = 4), malaria (N = 9), and
tuberculosis (N = 4). Samples from 30 healthy blood bank
donors were used as controls.
Post-therapeutic evaluation of antibodies in CL and ML.
For the serological follow-up, 12 patients with CL and
14 patients with ML were examined at three different time
periods: at a baseline before the initiation of the therapy (T0)
and 6 (T1), and 12 months (T2) after the onset of therapy. At
T0, CL patients had a disease evolution time varying from 0.2
to 30 years (median = 0.45; interquartile 25–75% = 0.30–0.80),
and ML patients had a disease evolution time ranging from 0.3
to 56 years (6.5; 1–40) (Table 1).
ELISA. All sera were tested for immunoglobulin G (IgG)
antibodies at 1:50 dilution in the ELISA using rHsp83 (ELISA-
rHsp83) or whole L. major-like parasite lysate (ELISA–L.
major-like) as previously described.14,24 For both antigens, the
cutoff point was determined using a receiver operating charac-
teristic (ROC) curve.33 The reactivity index (RI) was calculated
for each sample by dividing the sample absorbance value by the
cutoff. Samples were considered positive if the RI value was ³ 1.
Statistical analysis. The sensitivity and specificity of tests and
the 95% confidence intervals (95% CIs) were calculated using
the ROC curve. The results were compared using McNemar’s
test. The agreement between the ELISA results with rHsp83 or
L. major-like antigen was estimated by the k-index. Mann–
Whitney rank sum test (two groups) and Friedman repeated
measures analysis of variance on Ranks and Tukey test (three
or more groups) were used to compare medians.
Ethical issues. All participants gave informed consent indi-
vidually before giving the blood samples. This study was
approved by the Ethics Committees of the Instituto deMedicina
Tropical de Sao Paulo, Universidade de Sa˜o Paulo and the
Hospital das Clinicas, Faculdade de Medicina, Universidade
de Sa˜o Paulo.
RESULTS
Performance of ELISA-rHsp83 compared with ELISA–L.
major-like. The ROC curve was generated from 56 leishman-
iasis patient samples and 30 healthy blood bank samples
assayed by ELISA-rHsp83 (Figure 1A) and ELISA–L.
major-like (Figure 1B). To reach a maximum specificity
(95% CI) of 100.0% (88.43–100.0%), cutoff values were
0.070 for ELISA-rHsp83 and 0.190 for ELISA–L. major-like.
Using rHsp83 as the antigen in the ELISA assay led to a
significantly higher sensitivity in detecting anti-Leishmania
antibodies compared with using L. major-like antigen (P =
0.013, McNemar’s test) (Table 2). Strong agreement between
the evaluated antigens was observed, with k = 0.807 (0.682–
0.932). Figure 2 shows the reactivity of all tested serum sam-
ples with either antigen.
ELISA-rHsp83 and ELISA–L. major-like cross-reactivity
to other infectious disease samples.We found an overall spec-
ificity (95% CI) of 97.47% (91.15–99.69%) and 70.89% (59.58–
80.57%) for ELISA-rHsp83 and ELISA–L. major-like anti-
gens (Table 3), respectively, in serum samples from patients
with other infectious diseases. The difference in performance
of the two antigens was significant (P < 0.001, McNemar’s test).
Table 1
Characteristics of 26 TL patients, including clinical form, duration of
disease at baseline, number of relapses, and disease status
Time Relapses Cured
CL
0.8 0 Yes
0.4 1 Yes
0.3 1 Yes
0.5 2 Yes
0.3 0 Yes
0.2 1 Yes
0.8 0 Yes
0.3 0 Yes
1.0 0 Yes
0.3 1 Yes
30.0 1 Yes
0.6 0 Yes
ML
5.0 1 Unknown
0.5 1 Yes
0.7 1 Yes
16.0 0 Yes
0.3 0 Yes
53.0 0 Yes
50.0 1 Unknown
20.0 1 Yes
8.0 1 Yes
1.0 0 Yes
4.0 1 Yes
40.0 1 Yes
56.0 1 Yes
1.0 3 Yes
Relapses = number of relapses; time = disease duration at baseline in years; unknown = up
to the collection of the third sample, there was no report of the patient being cured; yes =
patient was reported as cured before collection of the third sample.
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For samples from patients with Chagas disease, ELISA
specificity was significantly higher with rHsp83 than L.
major-like antigen (P < 0.001, McNemar’s test). In the sera
from patients with other infectious disease (excluding Chagas
disease), both antigens had the same specificity: 96.43% (95%
CI = 87.69–99.56%; P = 0.617, McNemar’s test). Non-specific
reactions with rHsp83 antigen were observed with samples
from aspergillosis and toxoplasmosis patients. With the L.
major-like antigen, 21 of 23 (91.30%) serum samples from
Chagas disease patients showed cross-reactivity (Figure 3).
Post-therapeutic evaluation of anti-Leishmania antibody
titers in ELISA-rHsp83 in CL and ML. We found no signifi-
cant difference when assessing the post-therapeutic antibody
levels in 26 patients with TL (CL = 12 and ML = 14) using
ELISA-rHsp83 (Friedman repeated measures analysis of var-
iance on ranks: ML [P = 0.607], CL [P = 0.205]). In contrast,
ELISA–L. major-like median values showed a progressive
decrease; the medians were significantly higher at T0 com-
pared with T1 and T2 in ML (P = 0.0003) and at T0 compared
with T2 in CL (P = 0.0023) (Figure 4).
DISCUSSION
Early diagnosis of leishmaniases is vital to avoid permanent
damage, sequelae, and even death, depending on the disease
form. Although detection of the parasite confirms diagnosis,
the lack of detection does not exclude the presence of the
disease or infection, because parasitological methods have
low sensitivity.3,7,31,34–36
In this study, we evaluated L. infantum rHsp83 as an anti-
gen in ELISA for the diagnosis of CL, ML, and VL and
compared the results with L. major-like total promastigote
antigen. ELISA-rHsp83 was significantly more sensitive than
ELISA–L. major-like when comparing results from all leish-
maniasis patients (P = 0.013) and TL (P = 0.041). Previously,
Guimara˜es and others16 used ELISA–L. major-like and
reported low sensitivity (66.3%) and specificity (77.5%) for
TL patients, whereas Barroso-Freitas and others13 obtained
better results using ELISA-L. braziliensis (97.5% sensitivity
and 100.0% specificity) for TL patients. Using seven L.
infantum-derived recombinant proteins to test TL sera,
Hsp70 was considered the most promising, with 65.0% sensi-
tivity and 92.0% specificity.23
For VL patients, several groups have tested ELISA-L.
infantum rK39 and found sensitivity/specificity values of
88.6%/92.4%37 and 100%/96%.38 ELISA-rK39 has high diag-
nostic and prognostic use in human immunodeficiency virus
(HIV) -infected patients coinfected with L. infantum.39 Reac-
tivity of the widely used immunochromatographic test using
the rK39 antigen was shown to vary depending not only on
the patients’ origins but also, the product source.20
Although rK39 has been important for VL diagnosis, this
antigen does not allow detection of antibodies in CL or ML.40
However, the recombinant Hsp83 antigen detects VL, CL,
and ML with high sensitivity (100.0%), a great advantage
over the previously mentioned antigens.
Cross-reactivity of Leishmania antigens with sera samples
from geographic areas where other protozoa diseases, partic-
ularly Chagas disease, overlap with leishmaniasis is common.
Total promastigote antigen is known to cross-react with sera
positive for several other infectious diseases, especially
Chagas disease.24,30,39 To overcome such non-specific reac-
tions, several recombinant proteins have been tried with vary-
ing success. In this study, we obtained maximum indices with
both ELISA-rHsp83 and ELISA–L. major-like for healthy
blood bank samples. However, for serum samples from
patients with other infectious diseases, rHsp83 was signifi-
cantly more specific, particularly with respect to Chagas dis-
ease samples (P < 0.001). Souza and others23 obtained 90%
specificity with rHsp70, whereas we found 100.0% specificity
with rHsp83 in the Chagas disease samples. Aspergillosis and
toxoplasmosis serum samples provided non-specific reactions
with rHsp83, but the values were near the cutoff level and had
lower positivity than has been observed in other studies.31,41
In the present study, a significant decrease in antibody levels
detected by ELISA–L. major-like was observed 6 months
after the onset of therapy in ML patients and 12 months
Table 2
Sensitivity and specificity of ELISA-rHsp83 and ELISA–L. major-like
Samples N
ELISA-rHsp83 ELISA–L. major-like
Sensitivity (%) CI (%) Sensitivity (%) CI (%)
CL 12 100.0 73.54–100.0 83.33 51.59–97.91
ML 14 100.0 76.84–100.0 71.43 41.90–91.61
VL 30 100.0 88.43–100.0 93.33 77.93–99.18
Total 56 100.0* 93.62–100.0 87.50 75.93–94.82
Sensitivity (%) CI (%) Sensitivity (%) CI (%)
Normal
control
30 100.0 88.43–100.0 100.0 88.43–100.0
*P = 0.013 compared with ELISA–L. major-like (McNemar’s test).
Figure 1. ROC curve with leishmaniasis (N = 56) and control blood bank (N = 30) samples. (A) ELISA-rHsp83 generated a cutoff value of
0.070. (B) ELISA–L. major-like generated a cutoff value of 0.190.
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Figure 2. Reactivity index of sera from ML (N = 14), CL (N = 12), VL (N = 30), Chagas disease (CH; N = 23), other infectious diseases (OP;
N = 56), and control blood bank donors (NC; N = 30) in (A) ELISA-rHsp83 and (B) ELISA–L. major-like.
Table 3
Specificity (%) of ELISA-rHsp83 and ELISA–L. major-like for other infectious disease samples
Samples N
ELISA-rHsp83 ELISA–L. major-like
Specificity (%) CI (%) Specificity (%) CI (%)
Chagas disease 23 100.0* 85.18–100.0 8.70 1.07–28.04
Blastomycosis 7 100.0 59.04–100.0 85.71 42.13–99.64
Histoplasmosis 6 100.0 54.07–100.0 83.33 35.88–99.58
Aspergillosis 5 80.00 28.36–99.49 100.0 47.82–100.0
Cromomycosis 7 100.0 59.04–100.0 100.0 59.04–100.0
Toxoplasmosis 14 92.86 66.13–99.82 100.0 76.84–100.0
Cytomegalovirosis 4 100.0 39.76–100.0 100.0 39.76–100.0
Malaria 9 100.0 66.37–100.0 100.0 67.37–100.0
Tuberculosis 4 100.0 39.76–100.0 100.0 39.76–100.0
Total 79 97.47* 74.97–91.90 70.89 58.25–79.47
*P < 0.001 compared with ELISA–L. major-like (McNemar’s test).
Figure 3. (A) ELISA-rHsp83 and (B) ELISA–L. major-like cross-reactivity with other infectious disease samples: NC (N = 30), blastomycosis
(Pb; N = 7), histoplasmosis (Hc; N = 6), aspergillosis (Af; N = 5), chromomycosis (Cr; N = 7), toxoplasmosis (toxo; N = 14), cytomegalovirosis
(CMV; N = 4), CH (N = 23), malaria (Mal; N = 9), and tuberculosis (TB; N = 4).
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after therapy onset in CL patients, independent of the thera-
peutic response. Using ELISA-L. amazonensis, Romero and
others18 also observed a decrease in antibody levels in CL
patients after treatment that was unrelated to therapeutic
responses. In contrast, we did not detect a significant decrease
in antibody levels post-treatment as measured by the ELISA-
rHsp83. Control of cure by serological tests is a controversial
subject in the literature.42 The persistence of antibodies after
treatment could indicate the continued presence of viable
parasites, raising the possibility of a relapse.43
We believe that L. infantum-rHsp83 is a good antigen for
use in the serodiagnosis of leishmaniases. Because of its high
specificity and sensitivity and insignificant cross-reactivity
with other infectious diseases, we suggest the ELISA-rHsp83
as a routine confirmatory serological assay for the diagnosis
of Leishmania infection.
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